“…There is a large class of pharmacologically important pyrimidine derivatives that act as dihydrofolate reductase (DHFR) inhibitors (Hitchings, 1989), as well as compounds with anti-HIV (Holý, 2003;De Clercq and Holý, 2005), anti-adenovirus (Naesens et al, 2005), and anti-HBV activities (Ying et al, 2005), inhibitors of tetrahydrobiopterin synthesis Kolinsky and Gross, 2004), regulators of pain sensitivity and persistence (Tegeder et al, 2006), antidepressants (Arvanitis et al, 1999), compounds which suppress accumulation of cytokine-induced NF-jB (Ikemoto et al, 2008), inhibitors of EGFR and Her-2 tyrosine kinases (Suzuki et al, 2012) and cyclin-dependent kinases as potential drug candidates for cancer therapy (Beattie et al, 2003;Breault et al, 2003). Substitution at position 5 of the pyrimidine moiety has been used in the past to improve the biological property of several pharmacologically interesting pyrimidine derivatives with anti-HIV (Hocková et al, 2003(Hocková et al, , 2004 or anti-influenza activity (Jansa et al, 2012), with inhibitory activity against human thymidine phosphorylase (Nencka et al, 2007) or with antioxidative activity (Procházková et al, 2012a, b).…”